GOSSAMER BIO, INC. Increase (Decrease) in Receivables
GOSSAMER BIO, INC. (GOSS) reported Increase (Decrease) in Receivables of -$6.12 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInReceivables · last filed 2026-08-13
- GOSSAMER BIO, INC. increase (decrease) in receivables for the quarter ending 2026-06-30 was -$3.15M, a 415.96% decline year-over-year.
- GOSSAMER BIO, INC. increase (decrease) in receivables for the quarter ending 2026-03-31 was -$2.98M, a 338.96% decline year-over-year.
- GOSSAMER BIO, INC. increase (decrease) in receivables for the quarter ending 2025-12-31 was $2.98M.
- GOSSAMER BIO, INC. increase (decrease) in receivables for the quarter ending 2025-09-30 was $1.66M, a 43.76% decline year-over-year.
- GOSSAMER BIO, INC. increase (decrease) in receivables for fiscal 2025 was $6.89M, a 29.06% increase from fiscal 2024.
- GOSSAMER BIO, INC. increase (decrease) in receivables for fiscal 2024 was $5.34M.
- GOSSAMER BIO, INC. increase (decrease) in receivables for fiscal 2023 was $0.00.
- GOSSAMER BIO, INC. increase (decrease) in receivables for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Receivables 3 month | Increase (Decrease) in Receivables 6 month | Increase (Decrease) in Receivables 9 month | Increase (Decrease) in Receivables 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$6.12M 10-Q · filed 2026-08-13 | -$3.14M derived: sum of 3 quarters · filed 2026-08-13 | -$1.47M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$2.98M 10-Q · filed 2026-05-15 | $9.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.67M derived: sum of 3 quarters · filed 2026-05-15 | $2.67M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $4.65M derived: sum of 2 quarters · filed 2026-03-17 | $5.64M derived: sum of 3 quarters · filed 2026-08-13 | $6.89M 10-K · filed 2026-03-17 |
| 2025-09-30 | $1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.66M derived: sum of 2 quarters · filed 2026-08-13 | $3.90M 10-Q · filed 2025-11-05 | $2.65M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $996.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.24M 10-Q · filed 2026-08-13 | $991.00K derived: sum of 3 quarters · filed 2026-08-13 | $3.95M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.25M 10-Q · filed 2026-05-15 | -$5.00K derived: sum of 2 quarters · filed 2026-05-15 | $2.95M derived: sum of 3 quarters · filed 2026-05-15 | $6.58M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.71M derived: sum of 2 quarters · filed 2026-03-17 | $5.34M derived: sum of 3 quarters · filed 2026-03-17 | $5.34M 10-K · filed 2026-03-17 |
| 2024-09-30 | $2.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $6.59M derived: sum of 2 quarters · filed 2025-11-05 | $6.59M 10-Q · filed 2025-11-05 | $6.59M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $3.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $3.63M 10-Q · filed 2025-08-05 | $3.63M derived: sum of 3 quarters · filed 2026-03-17 | $3.63M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 10-K · filed 2026-03-17 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-12 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |